Corbus Pharmaceuticals Holdings, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director and Officer Trading Arrangements
On March 11, 2026, Yuval Cohen, Ph.D., the Company's Chief Executive Officer and a member of the board of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 270,075 shares of the Company's common stock. Pursuant to this plan, Dr. Cohen may sell shares of common stock beginning on June 14, 2026, subject to the terms of the agreement, and the plan terminates on March 16, 2027. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
On March 11, 2026, Sean Moran, the Company's Chief Financial Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 124,852 shares of the Company's common stock. Pursuant to this plan, Mr. Moran may sell shares of common stock beginning on June 14, 2026, subject to the terms of the agreement, and the plan terminates on March 16, 2027. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
On March 11, 2026, Anne Altmeyer, Ph.D., amember of the board of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 4,800 shares of the Company's common stock. Pursuant to this plan, Dr. Altmeyer may sell shares of common stock beginning on June 9, 2026, subject to the terms of the agreement, and the plan terminates on June 8, 2027. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
On March 11, 2026, John Jenkins, M.D., amember of the board of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 7,453 shares of the Company's common stock. Pursuant to this plan, Dr. Jenkins may sell shares of common stock beginning on June 9, 2026, subject to the terms of the agreement, and the plan terminates on June 8, 2027. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
On March 11, 2026, Winston Kung, amember of the board of directors, adopted a Rule 10b5-1 plan providing for the sale of up to 4,800 shares of the Company's common stock. Pursuant to this plan, Mr. Kung may sell shares of common stock beginning on June 9, 2026, subject to the terms of the agreement, and the plan terminates on June 8, 2027. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
No other directors or officers adopted, modified orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the first quarter of 2026.
-24-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.